基于随机对照试验真武汤治疗老年慢性心力衰竭临床疗效的Meta分析*

赵博雅; 王耀健; 郭亚鑫; 陈露莹; 谭颖子; 蒋跃绒

doi:10.3969/j.issn.1674-7593.2026.03.009

国际老年医学杂志 ›› 2026, Vol. 47 ›› Issue (3) : 315 -323. DOI: 10.3969/j.issn.1674-7593.2026.03.009

论著

基于随机对照试验真武汤治疗老年慢性心力衰竭临床疗效的Meta分析^*

^1**

作者信息 +

Meta-analysis of the clinical efficacy of Zhenwu decoction in treating chronic heart failure in the elderly based on randomized controlled trials

^1**

Author information +

文章历史 +

PDF (2625K)

摘要

目的基于Meta分析方法探讨真武汤治疗老年慢性心力衰竭的临床疗效与治疗安全性。方法系统检索中国知网、中国生物医学文献服务系统、万方、中华医学期刊网、中国临床试验注册中心、国际传统医学临床试验注册平台、中文科技期刊数据库、the Cochrane Library、Embase、PubMed、Web of Science等中英文数据库,检索自建库至2025年11月收录关于真武汤治疗老年慢性心力衰竭的随机对照试验。采用Revman5.4软件和Stata18.0软件对数据进行Meta分析。结果共纳入17项随机对照临床研究,总样本量1 782例患者,试验组与对照组各891例患者。Meta分析结果显示:两组患者在临床疗效、中医证候积分、左心室射血分数、左心室舒张末期内径、左心室收缩末期内径、氨基末端B型利钠肽前体、不良反应发生率方面比较,差异具有统计学意义(P<0.05)。结论真武汤治疗老年慢性心力衰竭临床疗效确切,并且安全性良好,降低了不良反应发生率。

Abstract

Objective A meta-analysis-based investigation into the clinical efficacy and safety of Zhenwu Decoction in treating chronic heart failure in the elderly. Methods The system searches Chinese and English databases such as CNKI, China Biomedical Literature Service System, Wanfang, Chinese Medical Journals Network, China Clinical Trial Registry, International Traditional Medicine Clinical Trial Registration Platform,CSTJ, the Cochrane Library, Embase,PubMed, and Web of Science, with data collection up to November 2025, to include randomized controlled trials on the treatment of chronic heart failure in the elderly with Zhenwu Decoction. Meta-analysis of the data was conducted using RevMan 5.4 and Stata 18.0 software. Results 17 randomized controlled clinical studies were included with a total sample size of 1 782 patients, with 891 patients in the experimental group and 891 patients in the control group.The meta-analysis results showed statistically significant differences between the two groups of patients in terms of clinical efficacy, TCM syndrome scores, left ventricular ejection fraction, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, N-terminal pro-B-type natriuretic peptide, and incidence of adverse reactions (P<0.05). Conclusion Zhenwu Decoction has definite clinical efficacy and good safety in treating elderly chronic heart failure, reducing the incidence of adverse reactions.